A monthly recap of the latest news about Alzheimer’s and dementia
US health officials aim to ‘transform’ Alzheimer’s disease research with $300 million data platform
The US National Institute on Aging is moving forward with efforts to build a real-world Alzheimer’s disease database as part of its aim to improve, support and conduct more dementia research. Read more here.
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
Alzheimer’s disease continued to progress at a slower rate in patients who took Leqembi even when they were off the treatment for an average of two years, the analysis found. Read more here.
AI Machine Learning Predicts Alzheimer’s Disease Risk
A new study published in Scientific Reports uses artificial intelligence (AI) machine learning (ML) and data from electronic health records (EHRs) to identify the important predictors for Alzheimer’s disease and finds that a person’s genetics outperforms age as a predictor for individuals who are 65 years of age and older. Read more here.
Why Is This New Generation of Alzheimer’s Drugs Such a Big Deal?
Here’s the difference between treating Alzheimer’s symptoms and actually changing the course of the disease itself. Read more here.
The new face of Alzheimer’s: Early stage patients who refuse to surrender
As the leader of three universities, Rebecca Chopp lived a life of the mind. So when she and her husband, Fred Thibodeau, learned she was in the early throes of Alzheimer’s disease, first, they grieved. Then, they decided to fight. Read more here.
Hospitalization for infection linked to higher dementia risk
Hospitalization due to infection may increase a person’s likelihood of developing dementia, according to a large NIA-funded observational study. Read more here.
